

## Microbiome-Based Skin Therapeutics

# Overview Naked Biome



## Naked Biome

- We are a translational microbiome-therapeutics company leveraging breakthrough science from the Human Microbiome Project to find microbiome-based applications for skin disease
- Lead product is the a **topical Live Biologic Therapeutic** for treatment of acne
- Science-based, entered Phase IB clinical trials

Illustration: Charis Tsevis



# Opportunity – Antibiotic Alternatives


## Problem-Abx resistance

- **Worldwide Problem**

- Cost US \$20 billion annually
- Dermatologists-long course Abx for acne, rosacea
- CDC/NIH/CARB-X initiatives to reduce Abx

- **Acne**


- \$4.5 Billion market
- 55-75% of *P.acnes* is resistant
- Little innovation in several decades
- Majority of Rx are combinations of generic drugs
- High side effect profile to topicals and orals



Naked Biome Solution-To provide Dermatologists better, safer, alternative treatments, develop an entirely new class of microbial-based therapeutics, and minimize antibiotic resistance



# Why now?-Genomic Revolution



## Sequencing Advances

- Cheaper
- Faster
- Strain-level resolution
- Enables microbial profiling for disease and health specific signatures
- Diseased bacteria have genotypic and phenotypic differences that have clinical relevance


- Before sequencing we knew 90% of facial skin flora was *P.acnes*, irrespective of health
- Now we know characteristics of bacteria that are associated with health and disease

# Summary Accomplishments in Seed De-risking

- ✓ **Technical Risk**- sourced, genotype,& phenotyped optimal candidate strains
- ✓ **Intellectual Property**-formal notice of allowances for IP covering pharmaceutical composition and methods of treatment
- ✓ **Manufacturing**-*P.acnes* GMP manufacturing process established
- ✓ **Regulatory**-obtained an approved FDA IND to enter Phase IB trials
- ✓ **Competition**-FTO completed with no immediate threats to our first product
- ✓ **Funding**-Raised \$5 million in seed capital
- ☐ **Clinical Trial**-Phase IB Clinical trial initiated to capture both safety and early engraftment/efficacy



NAKED BIOME



Presented by: Emma Taylor, MD | CEO & Co-Founder  
626-260-1230 | [emma.t@NakedBiome.com](mailto:emma.t@NakedBiome.com)